^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    iberdomide (CC-220)

    i
    Other names: CC-220, CC 220, CC220
    Company:
    BMS
    Drug class:
    CRL4-CRBN E3 ubiquitin ligase modulator
    Related drugs:
    18d
    A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=7, Active, not recruiting, Icahn School of Medicine at Mount Sinai | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Nov 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    dexamethasone • Empliciti (elotuzumab) • iberdomide (CC-220)
    18d
    Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trial. (PubMed, Lancet Haematol)
    IberCd is an all-oral and active combination for patients with relapsed and refractory multiple myeloma that showed clinically meaningful activity. This regimen offers a valuable treatment option for patients who have received two to four previous lines of therapy and compares favourably with other available treatments.
    P2 data • Journal
    |
    CRBN (Cereblon)
    |
    lenalidomide • cyclophosphamide • iberdomide (CC-220) • aspirin
    1m
    Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=66, Recruiting, Hackensack Meridian Health | Trial completion date: Nov 2025 --> May 2026 | Trial primary completion date: Nov 2025 --> May 2026
    Trial completion date • Trial primary completion date
    |
    carfilzomib • dexamethasone • iberdomide (CC-220)
    3ms
    CO43805: A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=121, Recruiting, Hoffmann-La Roche | Trial completion date: Mar 2029 --> Sep 2029 | Trial primary completion date: Mar 2027 --> Sep 2029
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • Lunsumio (mosunetuzumab-axgb) • iberdomide (CC-220) • Columvi (glofitamab-gxbm) • golcadomide (CC-99282)
    3ms
    Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study (clinicaltrials.gov)
    P1/2, N=49, Active, not recruiting, Mayo Clinic | Trial primary completion date: May 2027 --> Mar 2026
    Trial primary completion date
    |
    bortezomib • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • iberdomide (CC-220) • Hemady (dexamethasone tablets)
    4ms
    Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study (clinicaltrials.gov)
    P1/2, N=49, Active, not recruiting, Mayo Clinic | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    bortezomib • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • iberdomide (CC-220) • Hemady (dexamethasone tablets)
    4ms
    Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma (clinicaltrials.gov)
    P2, N=68, Recruiting, Emory University | Trial completion date: Oct 2025 --> Sep 2029 | Trial primary completion date: Sep 2025 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    iberdomide (CC-220)
    4ms
    KarMMa-7: Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=21, Terminated, Celgene | Completed --> Terminated; Business objectives have changed
    Trial termination
    |
    Abecma (idecabtagene vicleucel) • iberdomide (CC-220) • crenigacestat (LY3039478)
    4ms
    Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=135, Recruiting, AbbVie | Trial completion date: Jan 2037 --> Mar 2036
    Trial completion date • Adverse events
    |
    iberdomide (CC-220) • etentamig intravenous (ABBV-383 IV)
    5ms
    PLYCOM: A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=200, Recruiting, Hoffmann-La Roche | Trial completion date: May 2027 --> Jul 2028 | Trial primary completion date: May 2027 --> Jul 2028
    Trial completion date • Trial primary completion date
    |
    lenalidomide • dexamethasone • Actemra IV (tocilizumab) • iberdomide (CC-220) • cevostamab (RG6160)
    5ms
    An immunostimulatory CELMoD combination overcomes resistance to T-cell engagers caused by a high multiple myeloma burden. (PubMed, Blood)
    The addition of anti-PD1 and pomalidomide reduced the T cell exhaustion that occurs in response to TCE in high tumor burden settings. This was accompanied by more favorable T cell profiling, with limited expansion of regulatory T cells and exhaustion. In total, administering TCE following dexamethasone and iberdomide treatments provided deeper and more durable responses with reduced risk of CRS.
    Journal
    |
    IKZF1 (IKAROS Family Zinc Finger 1)
    |
    dexamethasone • pomalidomide • iberdomide (CC-220)
    5ms
    Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=135, Recruiting, TeneoOne Inc. | Trial primary completion date: Jun 2036 --> Mar 2036
    Trial primary completion date • Adverse events
    |
    iberdomide (CC-220) • etentamig intravenous (ABBV-383 IV)